Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01013961 · ClinicalTrials.gov registry record · Phase 2
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase 2 study, sponsored by ECOG-ACRIN Cancer Research Group.
- Terminated
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT01013961 is a Phase 2 study that was terminated before completion, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 31 participants.
The verdict
NCT01013961, a Phase 2 study, was terminated before completion, sponsored by ECOG-ACRIN Cancer Research Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies, such as rituximab and alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer killing substances to them. Giving rituximab together with alemtuzumab may kill more cancer cells. PURPOSE: This randomized phase II trial is studying two different doses of rituximab to compare how well they work when given together with alemtuzumab in treating older patients with progressive chronic lymphocytic leukemia.
Interventions
- BIOLOGICAL rituximab
- BIOLOGICAL alemtuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2011-04-27 |
| Est. Completion | 2015-04-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01013961
The ClinicalTrials.gov registry entry for NCT01013961 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ECOG-ACRIN Cancer Research Group, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which rituximab is the first listed.
NCT01013961 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01013961 about?
NCT01013961 is a clinical study titled "Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia". RATIONALE: Monoclonal antibodies, such as rituximab and alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer killing substances to them. Giving rituximab together with alemtuzuma...
What is the current status of trial NCT01013961?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2011-04-27. Estimated completion is 2015-04-14.
What interventions are being tested in trial NCT01013961?
The interventions under investigation include: rituximab (BIOLOGICAL), alemtuzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01013961?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.